title: The various assays for measuring activity states of factor VIIa in plasma and therapeutic products: Diagnostic value and analytical usefulness in various pathophysiological states.
abstract: The key coagulation factor FVII, and its activated form FVIIa, present a major interest for their role at the initiation phase of blood coagulation, and because they can activate all blood coagulation cascade, through the extrinsic, but also the intrinsic pathway. Blood activation initiated through FVII is first presented, as it is understood nowadays. Measurement of FVII and FVIIa were of main interest for epidemiological studies, but FVIIa contribution to assay results was only deduced. The introduction of specific FVIIa assays, functional or immunoassays, allowed measuring directly FVIIa without any interference of non-activated FVII, or other coagulation factors or their activated forms. The various methods available, and their characteristics are presented, with a special focus on two assays developed by our group for FVIIa (a clotting one and a chromogenic one). The FVIIa clotting assay shows evident superiority for measuring its activity in plasma, in pathophysiological conditions. The normal range is <2.5ng/ml, which represents less than 0.5% of the FVII protein. FVIIa is elevated in some pathological states. The chromogenic assay is of interest for assigning the potency of FVIIa concentrates, as it has a higher dynamic range. Both assays are fully automatable on laboratory instruments, and standardized in a satisfactory manner thanks to the use of the FVIIa concentrate WHO International Standard (NIBSC). The various applications and usefulness of FVIIa laboratory assays are discussed, for the measurement of therapeutic products, or for following recoveries in treated patients, including hemophiliacs with inhibitors, patients with severe bleeding risk (liver diseases, surgery, trauma, …), and lastly for measurement of its activity in therapeutic products.
authors.affiliation: Hyphen BioMed, Sysmex Group, Neuville sur Oise, France. Electronic address: jamiral@hyphen-biomed.com.
authors.forename: Jean
authors.initials: J
authors.lastname: Amiral
authors.affiliation: Hyphen BioMed, Sysmex Group, Neuville sur Oise, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Dunois
authors.affiliation: Hyphen BioMed, Sysmex Group, Neuville sur Oise, France.
authors.forename: Cédric
authors.initials: C
authors.lastname: Amiral
authors.affiliation: International Consultancy in Blood Components Quality/Safety Improvement, Audit/Inspection and DDR Strategies, London, UK. Electronic address: jseghatchian@btopenworld.com.
authors.forename: Jerard
authors.initials: J
authors.lastname: Seghatchian
mesh_terms: D001777:Blood Coagulation / Q000502:physiology*; D015942:Factor VIIa / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D010949:Plasma / Q000737:chemistry*
chemical_list: D015942:Factor VIIa
keywords: Chromogenic assay; FVIIa clotting assay; FVIIa in normals; FVIIa inhibitors; Therapeutic activated factor VII; Truncated tissue factor